BridgeBio Pharma Inc (NAS:BBIO)
$ 27.94 0.18 (0.65%) Market Cap: 5.23 Bil Enterprise Value: 6.44 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 48/100

BridgeBio Pharma Inc at Bank of America Healthcare Conference Transcript

May 11, 2022 / 11:40PM GMT
Release Date Price: $5.21 (-13.88%)
Gregory Allen Harrison
BofA Securities, Research Division - Analyst

Afternoon session of day 2 of the Bank of America Healthcare Conference. My name is Greg Harrison. I'm one of the biotech analysts here at BofA. It's my pleasure today to introduce Neil Kumar, CEO of BridgeBio.

Neil, would you like to start off with some opening remarks, then we can get into Q&A?

Neil Kumar
BridgeBio Pharma, Inc. - Co-Founder, President, CEO & Director

Yes, sure. That would be great. And thank you so much for having us. It's been a wonderful last day here.

Just as a reminder, BridgeBio Pharma is a clinical-stage biotechnology company that focuses on genetic diseases, both precision oncology, as well as Mendelian diseases with some 20-odd programs ranging from Phase III all the way back to preclinical discovery. And as I think most of you in the room know, we had a fairly significant setback at the beginning of this year with our ATTR cardiomyopathy program, Part A. And since then, basically, our strategic posture has been defined by a couple of

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot